Table 1 Patients’ characteristics
N = 55 | ||
|---|---|---|
Age | Median (range), years | 67 (53–83) |
Sex | Male/female | 36/19 |
ECOG PS | 0/1/2 | 14/37/4 |
Pathology | Adeno/adenosquamous/UN1 | 49/3/3 |
MSI status | MSI-H/MSS/UN1 | 0/34/21 |
UGT1A1 status | WT2/single hetero/homo/double hetero/UN1 | 19/26/6/3/1 |
Location | Head/body/tail | 23/18/14 |
Disease status | UR-LA3 / M4 | 3/52 |
Metastatic site | HEP/PER/LYM/PUL | 39/18/18/16 |
Number of metastatic sites | 0/1/≥2 | 3/25/27 |
Baseline CA19–9 | Median (range), U/mL | 315 (2–18,388) |
Prior irinotecan | Yes | 9 |
Number of previous courses of palliative chemotherapy | 1/2/3 | 25/28/2 |
NLR5 | < 5/ ≥ 5 | 42/13 |
GPS6 | 0/1/2 | 29/14/12 |